Ali Alsaadi, MD
Internal Medicine · Farmington Hills, MINPI 1912941477
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$694
- Sunovion Pharmaceuticals Inc.$573
- GSK$282
- Merck$260
- Teva Pharmaceuticals USA, Inc.$256
- AstraZeneca$247
- plus $4K from 51 others
Across 143 payments — averaging $3334.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seqirus USA Inc$428K
- AstraZeneca$44K
- Ferring Pharmaceuticals AS$5K
What the payments were for
- Travel & lodging$20%
- Food & beverage$6,12596%
- Education$2764%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$316
- ONYX FRONTIER$238
- LONHALA MAGNAIR$124
- CARDIOBLATE GEMINI$116
How this compares
$6,403 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 572 | $166,426 |
| OzempicSemaglutide | 62 | $71,495 |
| JardianceEmpagliflozin | 138 | $56,180 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $55,229 |
| FarxigaDapagliflozin Propanediol | 106 | $54,993 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $54,961 |
| AptiomEslicarbazepine Acetate | 66 | $41,380 |
| EntrestoSacubitril/Valsartan | 72 | $39,582 |
| JanuviaSitagliptin Phosphate | 108 | $32,039 |
| XareltoRivaroxaban | 80 | $30,974 |
| GemtesaVibegron | 130 | $30,726 |
| TivicayDolutegravir Sodium | 22 | $25,720 |
| VraylarCariprazine Hcl | 24 | $17,848 |
| EdurantRilpivirine Hcl | 11 | $16,976 |
| LinzessLinaclotide | 36 | $14,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $208 | $166,426572 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $282 | $78,459143 claims |
| Novo NordiskOzempic | $44 | $71,49562 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $104 | $69,349166 claims |
| AstraZenecaFarxiga, Symbicort | $247 | $61,428132 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $573 | $41,38066 claims |
| NovartisEntresto | $233 | $39,58272 claims |
| AbbVieVraylar, Linzess | $195 | $32,50160 claims |
| MerckJanuvia | $260 | $32,039108 claims |
| Johnson & JohnsonXarelto | $246 | $30,97480 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $192 | $30,726130 claims |
| Lilly USA, LLCTrulicity | $146 | $9,29215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Farmington Hills
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.